Navigation Links
US Dermatophytic Onychomycosis Market Discussed by GlobalData in Topical Report Now Available at MarketPublishers.com
Date:7/17/2013

London, UK (PRWEB) July 17, 2013

Dermatophytic onychomycosis (DO) is one of the most widespread fungal nail infections. It is not considered to be a life-threatening disease, but it can cause considerable pain and discomfort. At present, DO therapies consist of generics which are quite effective but are not as safe as their brand-name counterparts.

New topical DO therapies are predicted to be introduced in the offing, and they are likely to scale up the total drug treatment rates in the US owing to increasing physicians’ awareness of safer and more effective treatment options. Meanwhile, given their advantages such as a shorter duration of treatment, generic therapies represent a challenge to the development of the innovative therapies.

Topical research report “PharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022” elaborated by GlobalData has been recently published by Market Publishers Ltd.

Report Details:

Title: PharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022
Published: June, 2013
Pages: 146
Price:    US$ 4,995.00
http://marketpublishers.com/report/pharmaceuticals/drugs/dermatophytic-onychomycosis-do-us-drug-forecast-n-market-analysis-to-2022.html

The report provides in-depth insights into the US DO market. It uncovers vital general information on DO including its epidemiology, key symptoms and disease treatment; and also discloses historical and present data on the DO market revenues, annual therapy costs, treatment usage patterns, etc. The study contains a comprehensive pipeline analysis, evaluates the competitive environment, and presents details on the top companies operating in the market. The report examines major market drivers and restraints, outlines the market opportunities and challenges, characterizes prevailing development trends, and moreover, sheds light on the possible path of the market development through 2022.

Report Scope:

  •     Comprehensive overview of DO (epidemiology, general symptoms, disease treatment recommendations, etc.).
  •     All-round analysis of the US DO market.
  •     Historical and present data on the market performance.
  •     Description of the competitive scenario.
  •     Vital information on the major market opportunities.
  •     Clinical pipeline assessment.
  •     Profiles of the leading market players.
  •     Discussion of the important industry issues.
  •     Examination of the factors driving and restraining the market development.
  •     Detailed future market forecast up to 2022.

More research studies by the publisher can be found at GlobalData page.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10937702.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
2. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
3. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
4. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
5. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
6. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
7. ResearchMoz: Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market
8. GeneLink Marketing Efforts Poised to Show Results
9. Animal Biotechnology - Technologies, Markets and Companies
10. Gene Therapy - Technologies, Markets and Companies
11. Biomarkers - Technologies, Markets and Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... has an active R&D program for the development ... the Group has a unique research and development center in ... developing Bio Control products. Stockton has ... and regulatory guidelines, and is active in more than 35 ... Stockton,s flagship product Timorex Gold ® ...
(Date:2/6/2016)... ... February 06, 2016 , ... Contact:, Abby Mitchell, Communications Manager, ... Education Sponsors Teacher Training Program , Bite of Science Dinner Event to Strengthen ... Excellence in Education (CEE) will sponsor a Bite of Science professional enrichment session, ...
(Date:2/5/2016)... 2016 Amarantus BioScience Holdings, Inc. ... on developing products for Regenerative Medicine, Neurology and Orphan ... Designation (RPDD) from the US Food and Drug Administration ... was previously granted orphan drug designation (ODD) by the ... BioScience Holdings, Inc. (OTCQB: AMBS), a ...
(Date:2/4/2016)... RICHMOND, Calif. , Feb. 4, 2016  Sangamo ... therapeutic genome editing, announced today that Edward Lanphier ... an update on the progress of Sangamo,s ZFP Therapeutic ... company,s business strategy at 2:40 pm ET on Thursday, ... Annual Global Healthcare Conference. The conference is being ...
Breaking Biology Technology:
(Date:1/22/2016)... 22, 2016 ... of the  "Global Behavioral Biometric Market ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ... Biometric Market 2016-2020"  report to their ... Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ...
(Date:1/20/2016)... , Jan. 20, 2016   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... significant achievements are the result of the company,s laser ... iMedNet eClinical , it,s comprehensive, easy-to-use and highly ... --> Key MedNet growth achievements in 2015 ...
(Date:1/13/2016)... New York , January 13, 2016 ... Market Research has published a new market report titled ... Growth, Trends, and Forecast, 2015 - 2023. According to the ... in 2014 and is anticipated to reach US$1,625.8 mn ... 2015 to 2023. In terms of volume, the biometric ...
Breaking Biology News(10 mins):